These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 7833731)

  • 1. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
    BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
    Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
    Matthews DR; Cull CA; Stratton IM; Holman RR; Turner RC
    Diabet Med; 1998 Apr; 15(4):297-303. PubMed ID: 9585394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.
    Diabetes; 1985 Aug; 34(8):793-8. PubMed ID: 2862087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA; Goodman AM
    N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
    Turner R; Cull C; Holman R
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):136-45. PubMed ID: 8554206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).
    Agbaje OF; Coleman RL; Hattersley AT; Jones AG; Pearson ER; Shields BM; Holman RR;
    Diabetes Res Clin Pract; 2020 Aug; 166():108333. PubMed ID: 32702468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
    Adler AI; Coleman RL; Leal J; Whiteley WN; Clarke P; Holman RR
    Lancet; 2024 Jul; 404(10448):145-155. PubMed ID: 38772405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
    Marena S; Tagliaferro V; Montegrosso G; Pagano A; Scaglione L; Pagano G
    Diabete Metab; 1994; 20(1):15-9. PubMed ID: 8056129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?
    Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R
    J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
    Holman RR; Steemson J; Turner RC
    Diabet Med; 1987; 4(5):457-62. PubMed ID: 2959438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
    Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R
    Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.